Methylphenidate

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Methylphenidate is a central nervous system (CNS) stimulant, most often used for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy.[1] Methylphenidate hydrochloride has many brand names, including Tranquilyn and Ritalin.[2]

Theory[edit | edit source]

Methylphenidate increases activity in areas of the brain that are underactive in ADHD, including those involved in impulsive behavior and concentration.[2]


KPAX002 mitochondria nutrients[edit | edit source]

Dr. Jon Kaiser is performing clinical trials on a pharmaceutical product which he developed called Synergy (KPAX002) which is a combination of a low dosage of methylphenidate hydrochloride and over-the-counter mitochondrial support nutrients.

The KPAX002 mitochondria support nutrients are:

plus vitamins:

plus the minerals:

Evidence[edit | edit source]

The Canadian Consensus Criteria suggests using methylphenidate in the mornings only for fatigue, increased energy and alertness, and cautions that it may be habit forming.[3]

Methylphenidate has been used with success in a subset of ME/CFS patients. In 2016, Blockmans, et al, concluded that use of methylphenidate by CFS patients with concentration difficulties had a positive effect in about one out of three clinical trial patients.[4]

The phase II study concluded that 36% of the patients taking the Synergy treatment had a >20% reduction in overall ME/CFS symptoms after 28 days.[5] Kaiser patented the KPAX002 combination prior to publishing the trial results.[5]

Dosage[edit | edit source]

A low dose is suggested for ME/CFS of 5 - 10mg in the mornings.[3]

Notable studies[edit | edit source]

Risks and safety[edit | edit source]

A wide variety of side effects have been reported, some of which need immediate medical attention.

Common side effects include suicidality, mood swings and heart problems.[1]

Costs and availability[edit | edit source]

Prescription only[1]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. 1.0 1.1 1.2 "Methylphenidate Tablets - FDA prescribing information, side effects and uses". Drugs.com. Retrieved September 28, 2020.
  2. 2.0 2.1 "Methylphenidate Hydrochloride 5mg tablets". Drugs.com. Retrieved September 28, 2020.
  3. 3.0 3.1 Carruthers, Bruce M.; Jain, Anil Kumar; De Meirleir, Kenny L.; Peterson, Daniel L.; Klimas, Nancy G.; Lerner, A. Martin; Bested, Alison C.; Flor-Henry, Pierre; Joshi, Pradip; Powles, AC Peter; Sherkey, Jeffrey A.; van de Sande, Marjorie I. (2003), "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Clinical Working Case Definition, Diagnostic and Treatment Protocols" (PDF), Journal of Chronic Fatigue Syndrome, 11 (2): 7–115, doi:10.1300/J092v11n01_02
  4. 4.0 4.1 Blockmans, Daniel; Persoons, Philippe (June 27, 2016). "Long-term methylphenidate intake in chronic fatigue syndrome". Acta Clinica Belgica. 71 (6): 407–414. doi:10.1080/17843286.2016.1200816. ISSN 1784-3286.
  5. 5.0 5.1 5.2 Kaiser, JD (July 15, 2015), "A prospective, proof-of-concept investigation of KPAX002 in chronic fatigue syndrome", International Journal of Clinical and Experimental Medicine, 8 (7): 11064–11074, PMID 26379906
  6. Montoya, Jose G; Anderson, Jill N; Adolphs, Danya L; Bateman, Lucinda; Klimas, Nancy; Levine, Susan M; Garvert, Donn W; Kaiser, Jon D (2018), "KPAX002 as a treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A prospective, randomized trial" (PDF), International Journal of Clinical and Experimental Medicine, 11 (3): 2890-2900